Latest Period
Q1 2026
Security Snapshot
FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) Institutional Ownership
CUSIP: 31447P100
13F Institutional Holders and Ownership History from Q3 2017 to Q1 2026
Institutions Reporting
90
Shares (Excl. Options)
16,201,228
Price
$6.15
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares, no par value
- Symbol
- FENC on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 16,201,228
- Total 13F value
- $99,641,723
- Portfolio coverage rank
- 0%
- Share change
- +626,451
- Value change
- +$2,876,181
- Number of holders
- 90
- Shares outstanding
- 34,474,972
- SEC-reported price per share
- $9.97
- Insider filing price
- $9.97
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- FENC - FENNEC PHARMACEUTICALS INC. - Common Shares, no par value is tracked under CUSIP 31447P100.
- 90 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 96 to 90 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $119,646,530 to $99,641,723.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 90 institutions filings for Q1 2026.
Security key
31447P100
Latest holder period
Q1 2026
13F holders
90
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
FENC full holder history
FENNEC PHARMACEUTICALS INC. SEC filings
FENNEC PHARMACEUTICALS INC. company facts
FENNEC PHARMACEUTICALS INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 31447P100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
FENC
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 8.8% | -10% | $19,465,811 | +$1,886,035 | 3,041,533 | +11% | Rosalind Advisors, Inc. | 31 Mar 2026 |
| Sonic Fund II, L.P. | 8.2% | $21,503,685 | 2,799,959 | Kam Lawrence | 31 Dec 2025 | |||
| Southpoint Capital Advisors LP | 8% | $21,135,329 | 2,744,741 | Southpoint Master Fund, LP | 31 Dec 2025 | |||
| Solas Capital Management, LLC | 7.2% | -12% | $15,886,067 | +$1,480,186 | 2,482,198 | +10% | Solas Capital Management, LLC | 31 Mar 2026 |
| HIRSCHMAN ORIN | 5.7% | $12,186,826 | 1,981,501 | Orin Hirschman | 31 Mar 2026 | |||
| DG Capital Management, LLC | 4.1% | $6,342,597 | 1,114,692 | DG Capital Management, LLC | 31 Dec 2024 |
As of 31 Mar 2026, 90 institutional investors reported holding 16,201,228 shares of FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC). This represents 47% of the company’s total 34,474,972 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
45%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 8.4% | 2,908,201 | +11% | 7.3% | $17,885,436 |
| Southpoint Capital Advisors LP | 8% | 2,744,741 | 0% | 0.35% | $16,880,157 |
| Solas Capital Management, LLC | 7.2% | 2,482,198 | -3.1% | 8.8% | $15,265,518 |
| AIGH Capital Management LLC | 5.7% | 1,981,501 | +25% | 2.5% | $12,186,231 |
| BlackRock, Inc. | 4% | 1,368,176 | +11% | 0% | $8,414,284 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.6% | 897,144 | 0% | 0% | $5,517,436 |
| AWM Investment Company, Inc. | 2.1% | 720,135 | +1.2% | 0.49% | $4,428,830 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 371,738 | +25% | 0% | $2,286,188 |
| STATE STREET CORP | 1% | 359,055 | +1.8% | 0% | $2,208,188 |
| Potomac Capital Management, Inc. | 0.65% | 224,400 | +136% | 1.2% | $1,380,060 |
| MORGAN STANLEY | 0.61% | 211,108 | -13% | 0% | $1,298,314 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.49% | 168,473 | 0% | 0% | $1,036,109 |
| CITADEL ADVISORS LLC | 0.45% | 153,610 | -23% | 0% | $944,702 |
| NORTHERN TRUST CORP | 0.44% | 152,123 | +36% | 0% | $935,556 |
| Lion Point Capital, LP | 0.33% | 112,434 | 0% | 4.1% | $691,469 |
| Cornerstone Capital, Inc. | 0.3% | 105,000 | 0.06% | $645,750 | |
| GENDELL JEFFREY L | 0.24% | 83,024 | -41% | 0.01% | $510,597 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.24% | 83,005 | 0% | 0.01% | $510,481 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.18% | 63,537 | +11% | 0% | $390,753 |
| Nuveen, LLC | 0.18% | 60,948 | +134% | 0% | $374,831 |
| THOMPSON SIEGEL & WALMSLEY LLC | 0.17% | 57,226 | 0.01% | $352,000 | |
| Squarepoint Ops LLC | 0.16% | 56,510 | +331% | 0% | $347,537 |
| GOLDMAN SACHS GROUP INC | 0.16% | 55,664 | +28% | 0% | $342,334 |
| Eleva Capital SAS | 0.15% | 53,234 | 0.1% | $327,389 | |
| Bank of New York Mellon Corp | 0.15% | 52,462 | +6.6% | 0% | $322,643 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
35
Latest
Q1 2026
Rows shown
1-25 of 35
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 16,201,228 | $99,641,723 | +$2,876,181 | $6.15 | 90 |
| 2025 Q4 | 15,538,506 | $119,646,530 | +$11,219,093 | $7.70 | 96 |
| 2025 Q3 | 13,863,242 | $129,757,954 | +$2,614,052 | $9.36 | 83 |
| 2025 Q2 | 13,599,927 | $112,877,891 | +$2,365,581 | $8.30 | 77 |
| 2025 Q1 | 13,390,166 | $81,552,976 | -$1,522,792 | $6.09 | 68 |
| 2024 Q4 | 16,048,764 | $101,424,546 | +$7,283,101 | $6.32 | 64 |
| 2024 Q3 | 14,931,283 | $74,650,166 | +$2,539,947 | $5.00 | 62 |
| 2024 Q2 | 14,360,522 | $87,742,748 | -$6,402,237 | $6.11 | 62 |
| 2024 Q1 | 14,487,904 | $161,105,911 | -$6,099,282 | $11.12 | 64 |
| 2023 Q4 | 15,010,968 | $168,423,713 | +$8,238,895 | $11.22 | 55 |
| 2023 Q3 | 14,291,968 | $107,334,991 | +$1,444,870 | $7.51 | 54 |
| 2023 Q2 | 14,066,767 | $124,212,045 | +$9,438,707 | $8.83 | 54 |
| 2023 Q1 | 13,040,023 | $108,481,973 | +$4,197,539 | $8.32 | 53 |
| 2022 Q4 | 12,451,231 | $119,532,387 | -$8,641,346 | $9.60 | 42 |
| 2022 Q3 | 11,367,575 | $92,077,143 | +$913,826 | $8.10 | 29 |
| 2022 Q2 | 11,273,521 | $63,103,949 | -$835,989 | $5.63 | 24 |
| 2022 Q1 | 11,437,604 | $64,049,354 | +$542,291 | $5.60 | 24 |
| 2021 Q4 | 11,346,536 | $49,924,524 | -$2,427,096 | $4.40 | 26 |
| 2021 Q3 | 11,649,016 | $109,719,412 | -$3,040,624 | $9.42 | 30 |
| 2021 Q2 | 12,077,739 | $88,042,799 | -$14,218,632 | $7.29 | 36 |
| 2021 Q1 | 14,373,653 | $89,259,363 | -$593,443 | $6.21 | 49 |
| 2020 Q4 | 14,462,317 | $107,736,409 | +$5,043,456 | $7.45 | 48 |
| 2020 Q3 | 13,830,913 | $83,811,378 | -$1,125,208 | $6.06 | 51 |
| 2020 Q2 | 13,870,610 | $115,816,682 | +$37,949,605 | $8.35 | 53 |
| 2020 Q1 | 9,462,229 | $56,207,308 | +$983,452 | $5.94 | 25 |